• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在先前进行严重急性呼吸综合征冠状病毒2刺突蛋白皮内试验的部位接种BNT162b2加强疫苗后出现迟发性荨麻疹。

Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein.

作者信息

Triwatcharikorn Jidapa, Klaewsongkram Jettanong, Rerknimitr Pawinee

机构信息

Division of Dermatology, Department of Medicine, Faculty of Medicine, Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.

Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.

出版信息

Asia Pac Allergy. 2022 Jul 18;12(3):e27. doi: 10.5415/apallergy.2022.12.e27. eCollection 2022 Jul.

DOI:10.5415/apallergy.2022.12.e27
PMID:35966159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9353207/
Abstract

Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination with BNT162b2 at the site of previous intradermal injection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein. This reaction emphasized that delayed urticaria may not be an allergic reaction to excipient but rather to the immunogen as such as SARS-CoV-2 spike protein.

摘要

荨麻疹是2019冠状病毒病疫苗接种常见的皮肤不良事件。既往研究推测，BNT162b2疫苗中的聚乙二醇以及ChAdOx1 nCoV-19疫苗中的聚山梨酯等辅料为变应原。一名28岁女性在之前皮内注射严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的部位接种一剂BNT162b2加强针后出现荨麻疹。该反应强调，迟发性荨麻疹可能并非对辅料的过敏反应，而是对诸如SARS-CoV-2刺突蛋白这类免疫原的过敏反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/9353207/e87b0bb15d20/apa-12-e27-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/9353207/240d20394779/apa-12-e27-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/9353207/e87b0bb15d20/apa-12-e27-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/9353207/240d20394779/apa-12-e27-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/9353207/e87b0bb15d20/apa-12-e27-g002.jpg

相似文献

1
Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein.在先前进行严重急性呼吸综合征冠状病毒2刺突蛋白皮内试验的部位接种BNT162b2加强疫苗后出现迟发性荨麻疹。
Asia Pac Allergy. 2022 Jul 18;12(3):e27. doi: 10.5415/apallergy.2022.12.e27. eCollection 2022 Jul.
2
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.细胞和体液免疫应答在异源和同源 SARS-CoV-2 疫苗接种中的相互关系。
Allergy. 2022 Aug;77(8):2381-2392. doi: 10.1111/all.15247. Epub 2022 Feb 16.
3
The role of lymphocyte transformation tests (LTT) in suspected severe delayed hypersensitivity reactions following COVID-19 vaccination.淋巴细胞转化试验（LTT）在疑似 COVID-19 疫苗接种后严重迟发性超敏反应中的作用。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2182527. doi: 10.1080/21645515.2023.2182527. Epub 2023 Mar 13.
4
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.
5
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.接种 2019 年冠状病毒病（SARS-CoV-2）疫苗后发生 MOG 脑炎：病例报告及文献综述。
J Neurol. 2022 Oct;269(10):5198-5212. doi: 10.1007/s00415-022-11194-9. Epub 2022 Jun 23.
6
Evaluation of Patients with Vaccine Allergies Prior to mRNA-Based COVID-19 Vaccination.基于mRNA的新冠疫苗接种前疫苗过敏患者的评估
Vaccines (Basel). 2022 Jun 27;10(7):1025. doi: 10.3390/vaccines10071025.
7
Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection.腺病毒载体 ChAdOx1 疫苗和 BNT162b2 疫苗对 SARS-CoV-2 感染的保护持续时间。
Clin Drug Investig. 2022 Oct;42(10):799-806. doi: 10.1007/s40261-022-01195-x. Epub 2022 Aug 30.
8
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.接种 SARS-CoV-2 疫苗后的皮肤反应：一项对 405 例病例的西班牙全国性横断面研究。
Br J Dermatol. 2022 Jan;186(1):142-152. doi: 10.1111/bjd.20639. Epub 2021 Sep 21.
9
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用：来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
10
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.

引用本文的文献

1
APAAACI's activities and this issue.亚太过敏、哮喘与临床免疫学会的活动及本期内容。
Asia Pac Allergy. 2022 Jul 29;12(3):e33. doi: 10.5415/apallergy.2022.12.e33. eCollection 2022 Jul.

本文引用的文献

1
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.报告的 Moderna 和辉瑞 COVID-19 疫苗接种后皮肤反应：基于登记的 414 例病例研究。
J Am Acad Dermatol. 2021 Jul;85(1):46-55. doi: 10.1016/j.jaad.2021.03.092. Epub 2021 Apr 7.
2
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.疫苗与过敏反应：过去、当前的 COVID-19 大流行及未来展望。
Allergy. 2021 Jun;76(6):1640-1660. doi: 10.1111/all.14840. Epub 2021 Jun 4.
3
Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing.
荨麻疹/血管性水肿及辉瑞-生物科技公司新冠病毒疫苗引起的潮红反应中的皮肤试验：皮内试验的局限性
Allergy. 2021 Aug;76(8):2605-2607. doi: 10.1111/all.14839. Epub 2021 Apr 22.
4
COVID-19 vaccines: modes of immune activation and future challenges.COVID-19 疫苗：免疫激活模式和未来挑战。
Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x.
5
An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity.迟发型药物超敏反应诊断方法的最新综述
Front Pharmacol. 2021 Jan 12;11:573573. doi: 10.3389/fphar.2020.573573. eCollection 2020.
6
SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19.新冠病毒玫瑰糠疹样和荨麻疹样皮疹中严重急性呼吸综合征冠状病毒2刺突蛋白阳性
Br J Dermatol. 2021 Jun;184(6):1194-1195. doi: 10.1111/bjd.19833. Epub 2021 Mar 4.
7
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.巴瑞替尼治疗新冠肺炎：一项关于安全性和临床影响的初步研究。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.
8
False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence.2019冠状病毒病中逆转录聚合酶链反应的假阴性及核酸转换延长：而非复发
J Med Virol. 2020 Oct;92(10):1755-1756. doi: 10.1002/jmv.25855. Epub 2020 Jul 11.
9
Vaccine-associated hypersensitivity.疫苗相关过敏反应。
J Allergy Clin Immunol. 2018 Feb;141(2):463-472. doi: 10.1016/j.jaci.2017.12.971.
10
Non-IgE mediated mast cell activation.非 IgE 介导的肥大细胞活化。
Eur J Pharmacol. 2016 May 5;778:33-43. doi: 10.1016/j.ejphar.2015.07.017. Epub 2015 Jul 8.